Thyreos Inc

Bovine Respiratory Disease (BRD) Is the Leading Cause of Illness, Death, and Economic Loss by Infectious Disease in the Cattle Industry, Responsible for Over a Billion Dollars in Annual Costs in the United States. BRD Is Caused by a Complex of Viral and Bacterial Pathogens Including Bovine Herpesvirus Type 1 (BOHV-1), Bovine Respiratory Syncytial Virus (BRSV), and Bovine Parainfluenza Virus (BPIV-3). Current Vaccines Offer Limited Protection and Present Safety Concerns, Particularly Because BOHV-1 Modified-live Vaccines (MLVS) Retain the Ability to Establish Latency in the Nervous System, Allowing the MLV to Reactivate and Aggravatedisease Within Herds. to Address This, We Developed the BOHV-1 R2 Vaccine Platform, Which Debilitates the Ability of the MLV to Invade the Nervous System While Preserving Its Capacity Toinduce Strong Immunity.with This Project, We Aim to Build on the BOHV-1 R2 Platform by Engineering a Single, Integrated Vaccine That Expresses Protective Antigens From BRSV and BPIV-3. This Multiplexed Vaccine Is Designed to Provide Broad Protection Against the Three Major Viral Contributors to BRD While Maintaining an Improved Safety Profile and Reducing Vaccine Production Costs. by Creating a Safe, Effective, and Economically Viable Solution, We Hope to Improve Animal Health and Welfare, Decrease Reliance on Antibiotics, and Help Mitigate the Significant Financial Impact of BRD on Cattle Producers.